Summary of medicine characteristics - Versican Plus L4
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Versican Plus L4 suspension for injection for dogs
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose of 1 ml contains:
Active substances:
Suspension (inactivated):
| Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae strain MSLB 1089 Leptospira interrogans serogroup Canicola serovar Canicola, strain MSLB 1090 Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa, strain MSLB 1091 Leptospira interrogans serogroup Australis serovar Bratislava, strain MSLB 1088 | ALR* titre > 1:51 ALR* titre > 1:51 ALR* titre > 1:40 ALR* titre > 1:51 |
* Antibody micro agglutination-lytic reaction.
Adjuvant:
| Aluminium hydroxide | 1.8–2.2 mg. |
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Suspension for injection.
The visual appearance is as follows:
Whitish liquid with fine sediment.
4. CLINICAL PARTICULARS4.1 Target species
Dogs
-
4.2 Indications for use, specifying the target species
Active immunisation of dogs from 6 weeks of age:
-
– to prevent clinical signs, infection and urinary excretion caused by L. interrogans serogroup Australis serovar Bratislava,
-
– to prevent clinical signs and urinary excretion and reduce infection caused by L. interrogans serogroup Canicola serovar Canicola and L. interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae and
-
– to prevent clinical signs and reduce infection and urinary excretion caused by L. kirschneri serogroup Grippotyphosa serovar Grippotyphosa.
Onset of immunity :
4 weeks after completion of the primary course.
Duration of immunity :
At least one year following the primary vaccination course for all components of Versican Plus L4.
4.3 Contraindications
None.
-
4.4 Special warnings for each target species
A good immune response is reliant on a fully competent immune system. Immunocompetence of the animal may be compromised by a variety of factors including poor health, nutritional status, genetic factors, concurrent drug therapy and stress.
Vaccinate healthy animals only.
-
4.5 Special precautions for use
Special precautions for use in animals
Not applicable.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
-
4.6 Adverse reactions (frequency and seriousness)
A transient swelling (up to 5 cm) may commonly be observed at the injection site following subcutaneous administration in dogs. This can be painful, warm or reddened. Any such swelling will either have spontaneously resolved or be greatly diminished by 14 days after vaccination.
Anorexia and decreased activity are rarely observed.
Hypersensitivity reactions (e.g. gastrointestinal signs such as diarrhoea and vomiting, anaphylaxis, angioedema, dyspnoea, circulatory shock, collapse) may occur rarely. If such a reaction occurs, appropriate treatment should be administered without delay. Such reactions may evolve to a more severe condition which may be life-threatening.
Systemic reactions such as lethargy, hyperthermia and general malaise may occur very rarely.
Clinical signs of immune-mediated diseases, such as haemolytic anaemia, thrombocytopenia or polyarthritis have been reported in very rare cases.
The frequency of adverse reactions is defined using the following convention:
-
– very common (more than 1 in 10 animals treated displaying adverse reaction(s))
-
– common (more than 1 but less than 10 animals in 100 animals treated)
-
– uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
-
– rare (more than 1 but less than 10 animals in 10,000 animals treated)
-
– very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
-
4.7 Use during pregnancy, lactation or lay
Pregnancy and lactation:
Can be used during the second and third stages of pregnancy. Safety of the product during the early stage of pregnancy and during lactation have not been investigated.
4.8 Interaction with other medicinal products and other forms of interaction
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product other than Versican Plus DHPPi and Versican Plus Pi. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
-
4.9 Amounts to be administered and administration route
Subcutaneous use.
Dose and route of administration :
Shake well and administer immediately the entire contents (1 ml) of the product.
Primary vaccination scheme :
Two doses of Versican Plus L4 3–4 weeks apart from 6 weeks of age.
Vaccination against distemper, adeno, parvo and parainfluenza virus (DHPPi) :
If protection against DHPPi or Pi is required, dogs can be vaccinated with two doses of Versican Plus DHPPi or Versican Plus Pi mixed with Versican Plus L4 3–4 weeks apart from 6 weeks of age: The contents of a single vial of Versican Plus DHPPi or Versican Plus Pi should be reconstituted with the contents of a single vial of Versican Plus L4 (instead of the solvent). Once mixed, the contents of the vial should appear a whitish to yellowish colour with a slight opalescence. The mixed vaccines should be injected immediately via the subcutaneous route.
Re-vaccination scheme :
A single dose of Versican Plus L4 to be given annually.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
No data are available on the safety of an overdose.
-
4.11 Withdrawal period(s)
Not applicable.
-
5. IMMUNOLOGICAL PROPERTIES
Pharmacotherapeutic group: Immunologicals for canidae, inactivated bacterial vaccines.
ATC vet code: QI07AB01.
The vaccine is intended for the active immunisation of healthy puppies and dogs against diseases caused by Leptospira interrogans serogroup Australis serovar Bratislava, Leptospira interrogans serogroup Canicola serovar Canicola, Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa and Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae.
6. PHARMACEUTICAL PARTICULARS6.1 List of excipients
Suspension:
Sodium chloride
Potassium chloride
Potassium dihydrogen phosphate
Disodium phosphate dodecahydrate
Water for injections
6.2 Major incompatibilities
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products except those mentioned in section 4.8.
6.3 Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf life after first opening the immediate packaging: use immediately.
6.4 Special precautions for storage
Store and transport refrigerated (2 °C – 8 °C).
Do not freeze.
Protect from light.
-
6.5 Nature and composition of immediate packaging
Type I glass vial containing 1 ml closed with a chlorobutyl rubber stopper and aluminium cap.
Pack sizes:
Plastic box containing 25 vials (1 ml).
Plastic box containing 50 vials (1 ml).
Not all pack sizes may be marketed.
-
6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Zoetis Belgium SA
Rue Laid Burniat 1 1348 Louvain-la-Neuve
BELGIUM
8. MARKETING AUTHORISATION NUMBER(S)
EU/2/14/171/001
EU/2/14/171/002
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Date of first authorisation: 31/07/2014.
Date of last renewal: 08/04/2019.